HIV/AIDS Medications: Research on Isentress (Raltegravir)
 Top 10 HIV/AIDS-Related Clinical Developments of 2011 (December 1, 2011)
From The Body
- Conference Update From IAS 2011: Medication News (September/October 2011)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- Elvitegravir vs. Raltegravir: 48-Week Results in Treatment-Experienced Patients (July/August 2011)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- Raltegravir Still Effective at 5 Years (July 26, 2011)
From HIVandHepatitis.com
- Another NRTI-Sparing Regimen Does Well in Treatment-Naive Patients (July 25, 2011)
From aidsmap.com
- Five-Year Follow-Up: Isentress Comparable to Sustiva (July 21, 2011)
From AIDSmeds.com
- Raltegravir Combined With Kaletra Associated With Good Preservation of Bone Density Over 96 Weeks (July 19, 2011)
From aidsmap.com
- Dose Optimisation: 50 mg Ritonavir-Boosting, 3TC Dosing and Raltegravir Once-Daily (May/June 2011)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- Switching Isentress to Once a Day Is Less Effective (February 2011)
To read PDF, click here.
In Project Inform Perspective, from Project Inform
- Merck's HIV Drug Isentress Fails Once-a-Day Study (December 1, 2010)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
 Once-Daily Raltegravir "Not Non-Inferior" to Twice-Daily (November 29, 2010)
From Journal Watch
- HIV Drug Isentress Could Fight All Herpes Viruses (September 24, 2010)
From AIDSmeds.com
- Top Integrase Polymorphisms Do Not Confer Resistance to S/GSK1349572 or Raltegravir (September 15, 2010)
From National AIDS Treatment Advocacy Project
- Raltegravir Re-Use Response After Failure Depends on Mutation Pattern (September 15, 2010)
From National AIDS Treatment Advocacy Project
- Maintenance With Raltegravir/Atazanavir Usually Effective for 48 Weeks (Low Troughs, a Few Viral Rebounds) (September 13, 2010)
From National AIDS Treatment Advocacy Project
- Raltegravir Safe During Pregnancy (Summer/Fall 2010)
To read PDF, click here.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- Reyataz/Isentress Combo Spares Norvir and Nukes, but Is Integrase Resistance a Concern? (July 22, 2010)
From AIDSmeds.com
- Protease Inhibitor to Raltegravir Switch Maintains Viral Suppression, but NRTI Resistance Lowers Efficacy (July 22, 2010)
From aidsmap.com
- Raltegravir/Kaletra Combination Does Well (July 21, 2010)
A "nuke-sparing" combination of the integrase inhibitor raltegravir (Isentress) and the protease inhibitor drug lopinavir/ritonavir (Kaletra) looks highly promising, according to research presented to the conference.
From aidsmap.com
- New ViiV Integrase Inhibitor Effective Against Some Isentress-Resistant HIV Strains (July 20, 2010)
From AIDSmeds.com
- Protease Inhibitor-to-Isentress Switch Is Effective, Lipid Friendly (July 20, 2010)
From AIDSmeds.com
- Kaletra/Isentress Shows Promise as HIV Nuceleoside-Sparing Regimen for First-Line Treatment (July 20, 2010)
From AIDSmeds.com
- New Drugs and Simplified Treatments Demonstrate Potential for Treating HIV (AIDS 2010) (About Kaletra, Isentress, TBR-65 and S/GSK1349572) (July 20, 2010)
In The AIDS Beacon
- Raltegravir Lovefest, Vienna Edition: AIDS 2010 Studies Explore Various Strategies for Use -- A Blog Entry by Myles Helfand (July 20, 2010)
In The XVIII International AIDS Conference, from The Body
- Raltegravir Resistance Pattern Critical in Early Response to S/GSK1349572 (July 19, 2010)
From National AIDS Treatment Advocacy Project
- First-Line Lopinavir/r/Raltegravir (With No NRTIs) in Treatment Naive (July 19, 2010)
From National AIDS Treatment Advocacy Project
- Trading a Ritonavir-Boosted PI for Twice-Daily Raltegravir in SPIRAL (July 19, 2010)
From National AIDS Treatment Advocacy Project
- Once- Versus Twice-Daily Raltegravir When Switching From a PI (July 19, 2010)
From National AIDS Treatment Advocacy Project
- Raltegravir in Hepatitis Co-Infection (June 30, 2010)
To read PDF, click here.
In Treatment Update, from Canadian AIDS Treatment Information Exchange
- Raltegravir vs. Efavirenz: Focus on Lipodystrophy, Lipids and Other Changes (June 30, 2010)
To read PDF, click here.
In Treatment Update, from Canadian AIDS Treatment Information Exchange
- Raltegravir vs. Efavirenz -- Four Years Later (June 30, 2010)
To read PDF, click here.
In Treatment Update, from Canadian AIDS Treatment Information Exchange
- ICAAC Update (January/February 2010)
Three new drugs in development, plus Isentress with Reyataz.
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- Raltegravir Exhibits More Lipid-Friendly Profile Than Efavirenz, STARTMRK Subanalysis Finds (September 14, 2009)
An interview with Edwin DeJesus, M.D.
In The 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Safety and Efficacy of Raltegravir-Based Versus Efavirenz-Based Combination Therapy in Treatment-Naive Patients With HIV-1 Infection: A Multicentre, Double-Blind Randomised Controlled Trial (September 2009)
In The Lancet
- Drug Option for Patients Beginning HIV Treatment Studied (August 11, 2009)
In Kaiser Daily U.S. HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Researchers' Efforts to Develop HIV Treatment Examined (August 10, 2009)
In Kaiser Daily U.S. HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Raltegravir Moves Closer to Approval for First-Line Use in Europe (July 27, 2009)
A European regulatory committee has recommended expanding raltegravir's marketing authorization to include individuals initiating HAART. The recommendation comes days after trial data was presented about the safety and efficacy of the drug in treatment-naive patients.
From aidsmap.com
- Study Examines Efficacy of Isentress (Raltegravir) (July 23, 2009)
Isentress failed to "reduce low-level reservoirs of HIV," in a 53-participant study of HIV-positive patients whose viral loads were already at undetectable levels.
In Kaiser Daily U.S. HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Could Isentress (or Other Integrase Inhibitors) Be Used as an HIV Prevention Drug? (April 28, 2009)
From aidsmap.com
- Raltegravir as First-Line Therapy (Winter/Spring 2009)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- Study Explains Why Isentress Works Well and Resists Resistance (October 26, 2008)
From Project Inform
- Raltegravir May Cause Temporary Worsening of Pre-Existing Depression (September 2, 2008)
From aidsmap.com
- Natural Variation of HIV-1 Group M Integrase: Implications for a New Class of Antiretroviral Inhibitors (August 7, 2008)
In Retrovirology
- HIV-1 Integrase Inhibitors (June 23, 2008)
An overview on a new HIV medication class.
In The PRN Notebook
- ICAAC 2007 Study Summaries: An Interview With Joseph Eron, M.D. (September 20, 2007)
Dr. Eron discusses 48-week results of a study of raltegravir (MK-0518) in highly treatment-experienced HIVers.
From The Body PRO
- Briefing Document (Background Package): Raltegravir (PDF) (September 5, 2007)
FDA Antiviral Drugs Advisory Committee Meeting.
From U.S. Food and Drug Administration
- Faster Viral Decay With Raltegravir (July 24, 2007)
Treatment with raltegravir (RAL, MK-0518) produces more rapid viral load reductions than efavirenz (EFV, Sustiva, Stocrin) and significantly reduced the magnitude of the second phase of viral decay. Graeme Moyle, M.D., reports.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
- Cross-Resistance Between Integrase Inhibitors (July 24, 2007)
It appears that virologic failure with one of the current integrase inhibitors is likely to severely limit subsequent treatment options within that class according to a small cohort study. Graeme Moyle, M.D., reports.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
- FDA Grants Speedy Review for First HIV Integrase Inhibitor (June 29, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- 77% of Treatment-Experienced Patients on MK-0518 (raltegravir) Plus OBT Achieve Viral Load of Less Than 400 Copies: A Study Summary From David Cooper, M.D., and Roy Steigbigel, Ph.D. (February 27, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- 79% of Treatment-Experienced Patients on MK-0518 Plus OBT Achieve Viral Load of Less Than 400 Copies at Week 16 (February 27, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- The Next HIV Therapies (February 2007)
MK-0518, TMC125 and Maraviroc.
In HIV JournalView, from The Body PRO
- New Experimental Drug Integrase Inhibitor (MK-0518) (October/November 2006)
In Survival News, from AIDS Survival Project
- MK-0518 Demonstrates Potent Efficacy in Patients With Triple-Class-Resistant Virus: 24-Week Results (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
- The Integrase Inhibitor MK-0518 Demonstrates a Favorable Lipid Profile (September 27, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Potent Antiretroviral Effect Seen With the Integrase Inhibitor MK-0518 as Part of Combination ART in Treatment-Naive, HIV-1-Infected Patients (August 17, 2006)
In XVI International AIDS Conference
- EARMRK: Expanded Access Research Program for MK-0518 (PDF) (August 17, 2006)
From Merck & Co., Inc.
- Expanded Access Program for MK-0518, an Investigational HIV Integrase Inhibitor, Established for Patients With Limited Available Treatment Options (August 17, 2006)
Worldwide access program will be conducted along with phase III studies.
To read PDF, click here.
From Merck & Co., Inc.
- Integrase Inhibitors: The Next Wave? (Spring 2006)
A quick look at MK-518 and GS-9137.
To read PDF, click here.
In ACRIA Update, from AIDS Community Research Initiative of America
- Integrase Inhibitors (February 25, 2005)
[Archived Article]
To read PDF, click here.
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
|
Advertisement
|
Email
Glossary
